Cassava Sciences Inc (NASDAQ:SAVA)
| 45.78 Delayed Data As of Jan 14 |  +0.09 / +0.20%Today’s Change | 9.98 Today|||52-Week Range 146.16 | +4.76% Year-to-Date |
Latest SAVA News | Press Releases
| IVC Wealth Advisors LLC Buys West Pharmaceutical Services Inc, iShares J.P. ... Jan 13 / GuruFocus News - Paid Partner Content | Where Will Cassava Sciences Be in 1 Year? Jan 07 / MotleyFool.com - Paid Partner Content |
| Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs Jan 12 / Zacks.com - Paid Partner Content | 3 Healthcare Stocks That Could Rocket Higher in 2022 Jan 04 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 45.69 |
| Today’s open | 45.02 |
| Day’s range | 44.40 - 46.59 |
| Volume | 37,595 |
| Average volume (3 months) | 5,411,002 |
| Market cap | $1.8B |
Data as of 4:46pm ET, 01/14/2022
Growth & Valuation
| Earnings growth (last year) | +8.80% |
| Earnings growth (this year) | -232.29% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 17.49 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PRTAProthena Corporation... | +2.19 | +5.88% |
| ALLOAllogene Therapeutic... | +1.32 | +11.04% |
| ---- | ||
| PTGXProtagonist Therapeu... | +1.21 | +3.48% |
Data as of 4:00pm ET, 01/14/2022
Financials
| Next reporting date | March 30, 2022 |
| EPS forecast (this quarter) | -$0.33 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$6.3M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters Austin, Texas |
Forecasts
